Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • AJNR Case Collection
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • Special Collections
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
    • 2024 AJNR Journal Awards
    • Most Impactful AJNR Articles
  • Multimedia
    • AJNR Podcast
    • AJNR Scantastics
    • Video Articles
  • For Authors
    • Submit a Manuscript
    • Author Policies
    • Fast publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Manuscript Submission Guidelines
    • Imaging Protocol Submission
    • Submit a Case for the Case Collection
  • About Us
    • About AJNR
    • Editorial Board
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Other Publications
    • ajnr

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • AJNR Case Collection
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • Special Collections
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
    • 2024 AJNR Journal Awards
    • Most Impactful AJNR Articles
  • Multimedia
    • AJNR Podcast
    • AJNR Scantastics
    • Video Articles
  • For Authors
    • Submit a Manuscript
    • Author Policies
    • Fast publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Manuscript Submission Guidelines
    • Imaging Protocol Submission
    • Submit a Case for the Case Collection
  • About Us
    • About AJNR
    • Editorial Board
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

Welcome to the new AJNR, Updated Hall of Fame, and more. Read the full announcements.


AJNR is seeking candidates for the position of Associate Section Editor, AJNR Case Collection. Read the full announcement.

 

Research ArticleBrain

Prevalence and Topography of Small Hypointense Foci Suggesting Microbleeds on 3T Susceptibility-Weighted Imaging in Various Types of Dementia

H. Uetani, T. Hirai, M. Hashimoto, M. Ikeda, M. Kitajima, F. Sakamoto, D. Utsunomiya, S. Oda, S. Sugiyama, J. Matsubara and Y. Yamashita
American Journal of Neuroradiology May 2013, 34 (5) 984-989; DOI: https://doi.org/10.3174/ajnr.A3332
H. Uetani
aFrom the Departments of Diagnostic Radiology (H.U., T.H., M.K., F.S., D.U., S.O., Y.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Hirai
aFrom the Departments of Diagnostic Radiology (H.U., T.H., M.K., F.S., D.U., S.O., Y.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Hashimoto
bPsychiatry and Neuropathobiology (M.H., M.I.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Ikeda
bPsychiatry and Neuropathobiology (M.H., M.I.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Kitajima
aFrom the Departments of Diagnostic Radiology (H.U., T.H., M.K., F.S., D.U., S.O., Y.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Sakamoto
aFrom the Departments of Diagnostic Radiology (H.U., T.H., M.K., F.S., D.U., S.O., Y.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Utsunomiya
aFrom the Departments of Diagnostic Radiology (H.U., T.H., M.K., F.S., D.U., S.O., Y.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Oda
aFrom the Departments of Diagnostic Radiology (H.U., T.H., M.K., F.S., D.U., S.O., Y.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Sugiyama
cCardiovascular Medicine (S.S., J.M.), Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Matsubara
cCardiovascular Medicine (S.S., J.M.), Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Yamashita
aFrom the Departments of Diagnostic Radiology (H.U., T.H., M.K., F.S., D.U., S.O., Y.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: The prevalence and topography of small hypointense foci suggesting microbleeds on 3T SWI in various types of dementia have not been systematically investigated. The purpose of this study was to determine the prevalence and topography of SHF on 3T SWI in patients with different dementia subtypes.

MATERIALS AND METHODS: We included 347 consecutive patients (217 women, 130 men; age range, 42–93 years; mean age, 74 years) who attended our memory clinic and underwent 3T SWI. They were divided into 6 groups: subjective complaints, MCI, AD, DLB, VaD, and FTLD. Two neuroradiologists evaluated the number and location of SHF on SWIs. Statistical analyses were performed to evaluate inter- and intragroup differences.

RESULTS: Of the 347 patients, 160 (46.1%) exhibited at least 1 small hypointense focus. This was true in 86% with VaD, 54% with DLB, 48% with AD, 41% with MCI, 27% with FTLD, and 22% with subjective complaints. With the subjective complaints group as a reference, the odds ratio adjusted by age, sex, and arterial hypertension was 9.2 (95% CI, 2.0–43.6) for VaD; 5.4 (95% CI, 1.2–24.3) for AD; 3.1 for DLB (95% CI, 1.1–8.8); 2.0 for MCI (95% CI, 0.5–8.1); and 1.5 for FTLD (95% CI, 0.4–5.4). There was a significant lobar predilection for AD, DLB, and FTLD groups (P < .05).

CONCLUSIONS: On 3T SWI, patients with VaD, AD, and DLB manifested a high SHF prevalence. In patients with AD, DLB, and FTLD, the SHF exhibited a lobar predilection.

ABBREVIATIONS:

AD
Alzheimer disease
CI
confidence interval
DLB
dementia with Lewy bodies
FTLD
frontotemporal lobar dementia
MCI
mild cognitive impairment
SHF
small hypointense foci
VaD
vascular dementia

Dementia is a growing medical, social, and economic problem. Approximately 24 million individuals have this disease globally, and their number is expected to double every 20 years to reach 81 million by 2040.1 Among dementias, AD is the most common primary neurodegenerative disease.2 Patients with amnesic MCI are at high risk for progression to AD.3 VaD is induced by cerebrovascular disease; it is considered the most common secondary cause of dementia.4,5 Less common but important causes of dementia are DLB and FTLD.5,6

Small hypointense foci in the brain on T2*-weighted gradient recalled-echo and SWI are thought to be microbleeds.7⇓–9 SHF are associated with symptomatic intracerebral hemorrhage, hypertension, and advanced age.10⇓⇓⇓–14 Male sex, smoking, and diabetes mellitus may be risk factors for SHF.10,14,15 On MR imaging, SHF are associated with radiologic signs of small-vessel disease, white-matter hyperintensities, and lacunar infarcts.11,14,16⇓–18 Histologically, they represent previous extravasation of blood and are related to bleeding-prone microangiopathies of different origins (eg, lipohyalinosis, amyloid deposition).8 Deep subcortical SHF are thought to be associated with vascular risk factors,11 and lobar SHF are usually attributed to vascular β-amyloid deposits (cerebral amyloid angiopathy).11,19⇓–21

Among patients with cognitive disorders, those with AD, MCI, and VaD tend to have SHF.22 In healthy subjects, the prevalence of SHF detected by 2D T2*-weighted GRE imaging ranged from 0% to 21%14,23,24; it increased to 32% in patients with AD,25 to 20% in patients with MCI,22 and to 85% in patients with VaD.26 Although histologic studies found a relatively high prevalence of microhemorrhages in the brains of patients with DLB at postmortem examination,27 no MR imaging studies examining SHF in patients with DLB have been reported. Although there are a few studies of SHF detected on SWI of control subjects and patients with the limited type of dementia,21,28 no cohort studies have evaluated the prevalence and topography of SHF on 3T SWI in various types of dementia. The purpose of this study was to investigate the prevalence and topography of SHF on 3T SWI in patients with different dementia subtypes.

Materials and Methods

Study Population

All procedures followed the Clinical Study Guidelines of the Ethics Committee of Kumamoto University Hospital and were approved by the internal review board. A complete description of all procedures was provided to the patients, and written informed consent was obtained from them or their caregivers.

We collected data from 592 consecutive patients who attended the Dementia Clinic of the Department of Neuropsychiatry, Kumamoto University Hospital, from January 2008 to February 2010. All patients were examined comprehensively by 2 senior neuropsychiatrists (M.I., M.H.) having sufficient experience in examining patients with dementia. Routine laboratory and standardized neuropsychological tests, such as the Mini-Mental State Examination, brain MR imaging, and single-photon emission tomography were also performed; all results were incorporated into the diagnosis. The diagnoses were made by a team of neuropsychiatrists, neuropsychologists, and radiologists. We excluded 245 patients who met the following exclusion criteria: 1) severe behavioral problems that would make MR imaging difficult; 2) evidence of focal brain lesions on MR imaging such as posttraumatic brain injury or brain tumor; 3) diagnosis of depression, posttraumatic brain injury, idiopathic normal pressure hydrocephalus, or other neurodegenerative diseases (eg, corticobasal degeneration, progressive supranuclear palsy, Parkinson disease with dementia); 4) history of serious psychiatric diseases, substance abuse, or developmental abnormalities; 5) inability to obtain informed consent; or 6) SWI with severe motion or susceptibility artifacts. Consequently, clinical and MR imaging data on 347 patients were used in this prospective study.

All diagnoses were based on pre-established criteria: for AD, fulfilling the criteria for probable AD of the National Institute of Neurologic Disorders and Stroke/Alzheimer Disease and Related Disorders Association29; for VaD, fulfilling the criteria for probable VaD of the National Institute of Neurologic Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences30; for MCI, fulfilling the general criteria of the International Working Group on MCI31; for DLB, fulfilling the clinical criteria of the consortium on DLB32; and for FTLD, fulfilling the Lund-Manchester criteria for behavioral variant frontotemporal dementia, semantic dementia, or progressive nonfluent aphasia.33 There were 162 patients (47%) with AD, 51 (15%) with MCI, 41 (12%) with DLB, 33 (10%) with FTLD, and 28 (8%) with VaD. When all clinical investigation results were normal, the patients were recorded as having subjective complaints (n = 32, 9%). Hypertension was judged as present when either a systolic pressure of >140 mm Hg or a diastolic pressure of >90 mm Hg was demonstrated on repeat examinations or when a history of treatment for hypertension was present.

MR Imaging Protocol

MR imaging was performed on a 3T unit (Magnetom Trio; Siemens, Erlangen, Germany). The MR imaging protocol included axial SWI (64 sections per slab, FOV = 230 mm, matrix = 256 × 256, section thickness = 2 mm, voxel size = 0.9 × 0.9 × 2 mm, TE = 20 ms, TR = 27 ms, flip angle = 15°), axial FLAIR, axial T2-weighted turbo spin-echo, 3D T1-weighted magnetization-prepared rapid acquisition of gradient echo sequences and diffusion-weighted imaging, MR spectroscopy, and MR angiography. SWI processing was with software incorporated into the MR imaging system console (Siemens) according to published methods.34 SWI was constructed by multiplying magnitude by filtered phase images to enhance the susceptibility effect, followed by 16-mm minimum intensity projection reconstruction.

Evaluation of Microbleeds and Other Findings on MR Imaging

On a PACS workstation, all SWI was independently analyzed by 2 neuroradiologists (H.U., T.H.) blinded to clinical data. They reviewed divergent evaluations to reach a consensus. They assessed the number and location of SHF on 2-mm contiguous SWI; 16-mm minimum intensity projection SWI was also used to differentiate SHF from veins. SHF suggesting microbleeds were defined as small (<10 mm diameter), homogeneous, round foci of low signal intensity (Fig 1). Symmetric hypointensities in the globi pallidi or dentate nuclei thought to reflect physiologic calcification or iron deposits, flow void artifacts of pial blood vessels, and hyposignals inside a lesion compatible with an infarct were not recorded as SHF suggesting microbleeds because they could reflect hemorrhagic transformations. Because SWI has skull base artifacts that limit the view of the base of the brain, we excluded the evaluation of SHF in that location. SHF were counted throughout the brain and categorized as SHF in the basal ganglia/thalamus (including the internal and external capsule), infratentorial (brain stem and cerebellum), and lobar (cerebral cortex and subcortical and periventricular white matter) regions. SHF in the lobar region were subgrouped as frontal, temporal, parietal, and occipital. When at least 1 small hypointense focus was detected, the region or area of the brain was defined as SHF-positive.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

A 78-year-old woman with AD without arterial hypertension. Her Mini-Mental State Examination score was 8. On a 2-mm SWI image, 2 small hypointense foci are seen in the right occipital lobe (arrows).

With regard to assessment of small-vessel disease on MR imaging, image analysis was performed in consensus by 2 radiologists (H.U., T.H.). Lacunar infarcts were defined as small round- or oval-shaped infarcts of <15 mm in diameter, with high signal intensity on T2-weighted images; low signal intensity on magnetization-prepared rapid acquisition of gradient echo and FLAIR sequences, ruling out enlarged perivascular spaces; and patchy leukoaraiosis. Lacunar infarcts were considered present or absent when there was at least 1 in the basal ganglia/thalamus or brain stem. White matter hyperintensities were graded on FLAIR sequences by using a previously described method as grades 0–3 (absent, punctuate, early confluent, or confluent abnormalities).35

Statistical Analyses

Statistical analyses were performed with the Statistical Package for the Social Sciences, Version 19 (SPSS, Chicago, Illinois). Interobserver agreement between 2 readers of SWI with respect to the number of SHF-positive regions was determined by calculating the κ coefficient (κ < 0.20, poor; κ = 0.21–0.40, fair; κ = 0.41–0.60, moderate; κ = 0.61–0.80, good; κ = 0.81–0.90, very good; and κ > 0.90, excellent agreement). Inter- and intragroup differences were assessed with the χ2, Fisher exact, or Student t test. Group comparisons with respect to the number of SHF were performed by using the Kruskal-Wallis test. Crude and adjusted odds ratios and the accompanying 95% confidence interval were calculated for every diagnostic group by using the patients with subjective complaints as the reference group. To adjust for age, sex, and arterial hypertension, we performed logistic regression analyses between the subjective complaints group and each of the other groups. Differences of P < .05 were considered statistically significant.

Results

Prevalence of Microbleeds

Interobserver agreement between 2 readers of SWI with respect to the number of SHF-positive regions was very good (κ = 0.87). Among the 347 patients, 160 (46.1%) had at least 1 small hypointense focus, 30% had one, 17% had two, 20% had 3–5, and 33% had >5 SHF. The mean patient age at the time of the MR imaging study was 74.3 ± 8.8 years; 130 (37.5%) were men. The mean Mini-Mental State Examination score was 21.0 ± 5.3. The prevalence of SHF differed significantly with age, sex, hypertension, and Mini-Mental State Examination (P < .05). Among patients 75 years or older (n = 204), 55% harbored SHF compared with 33% in patients younger than 75 years (n = 143) (χ2 = 16.27, P = .0001). Men had a higher prevalence than women (57% versus 40%) (χ2 = 9.10, P = .0026); 66% of patients with and 29% of those without hypertension manifested SHF (χ2 = 44.06, P < .0001). There was a significant difference between microbleeds and Mini-Mental State Examination (SHF-positive: mean, 20.3 ± 5.2; microbleed-negative, mean, 21.7 ± 5.4; t = 2.44, P = .015). The median number of SHF (interquartile range) for each group was subjective complaints = 1 (1–2), MCI = 2 (1–7), AD = 3 (1–7), DLB = 2 (1–5), FTLD = 3 (2–5), and VaD = 15 (2–32).

As shown in Table 1, the prevalence of SHF among the groups differed significantly (P < .0001); 86% with VaD, 54% with DLB, 48% with AD, 41% of MCI, and 27% with FTLD harbored SHF. Of our patients with subjective complaints, 22% manifested SHF. Logistic regression analysis, adjusted for age, sex, and hypertension, showed that the adjusted odds ratio (95% CI) for SHF, by using the subjective complaints group as a reference, was 9.2 (2.0–43.6) for VaD, 5.4 (1.2–24.3) for AD, 3.1 (1.1–8.8) for DLB, 2.0 (0.5–8.1) for MCI, and 1.5 (0.4–5.4) for FTLD. There was a statistically significant difference between the subjective complaints and the VaD, AD, or DLB group (P < .05).

View this table:
  • View inline
  • View popup
Table 1:

Patient characteristics and SHF prevalence in each dementia subgroup

Topography of Microbleeds

The lobar region was the most frequent site of SHF in each group (Table 2 and Fig 2); 136 (39.2%) of the 347 patients were found to have at least 1 small hypointense focus in this region. The SHF prevalence of lobar, basal ganglia/thalamus, and infratentorial regions was 41%, 15%, and 14% for patients with AD; 44%, 12%, and 17% for those with DLB; and 27%, 6%, and 6% for those with FTLD, respectively. For these 3 groups, there was a significant difference in the SHF prevalence in the lobar versus basal ganglia/thalamus or infratentorial regions (P < .05) (Fig 2). This was not the case in patients with VaD, MCI, and subjective complaints. There were no statistically significant intragroup differences with respect to involvement of the frontal, temporal, parietal, and occipital areas in any of the groups.

View this table:
  • View inline
  • View popup
Table 2:

Topography of SHF in each dementia subgroupa

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Graph of the topography of small hypointense foci in the different dementia subgroups. Boxes illustrate the percentage of SHF in each region. In each group, the lobar region was the most frequent site of SHF. *In patients with DLB, AD, or FTLD, the prevalence of SHF in the 3 regions of the brain was significantly different (P < .05). BG/T indicates the basal ganglia/thalamus region; IT, infratentorial region; Lobar, lobar region.

Prevalence of White Matter Hyperintensities and Lacunar Infarcts

The prevalence of white matter hyperintensities and lacunar infarcts in each dementia subgroup is shown in Table 3. Lacunar infarcts were observed in 71 of 347 (20%) patients. In patients with dementia, 82% with VaD, 26% with MCI, 17% with DLB, 16% with AD, and 6% with FTLD harbored lacunar infarcts. Our patients with subjective complaints did not have lacunar infarcts. With regard to white matter hyperintensities, confluent white matter hyperintensities were seen in 42 of 347 (12%) patients. Confluent white matter hyperintensities were observed in 54% of patients with VaD, 16% with MCI, 9% with AD, 5% with DLB, and 3% with FTLD. Of our patients with subjective complaints, 3% manifested confluent white matter hyperintensities.

View this table:
  • View inline
  • View popup
Table 3:

Prevalence of white matter hypertensities and lacunar infarcts in each dementia subgroupa

Discussion

Our 3T SWI study disclosed a high prevalence of SHF among patients; 22% with subjective complaints, 27% with FTLD, 41% with MCI, 48% with AD, 54% with DLB, and 86% with VaD harbored SHF. Ours is the first study documenting the prevalence of SHF on SWI in patients with DLB and FTLD, to our knowledge. In healthy subjects or patients with subjective complaints, the prevalence of SHF depicted on 2D T2*-weighted gradient recalled-echo images ranged from 0% to 21%.14,23,24 It ranged from 18% to 32% in AD22,25 and from 65% to 85% in VaD22,26; in patients with MCI, it was reported to be 20%.22 On a 1.5T SWI study by Goos et al,28 the prevalence of SHF was 30% in subjective complaints, 39% in AD, and 44% in MCI. The sensitivity of SWI for microbleeds was reported to be 3–6 times higher than that of T2*-weighted gradient recalled-echo imaging.9,36 The depiction of microbleeds on SWI is reported to be more enhanced at 3T and 7T than at 1.5T.9,37 However, the prevalence of SHF on 3T SWI in our patients did not increase markedly compared with that on 1.5T SWI in the previous report.28 Although the exact reason is unknown, the difference in patient characteristics (eg, sex, arterial hypertension) might have affected the results.

The relative prevalence of SHF was different among our diagnostic groups. The adjusted odds ratio for SHF by using patients with subjective complaints as the reference was 9.2 for VaD, 5.4 for AD, 3.1 for DLB, 2.0 for MCI, and 1.5 for FTLD. A statistically significant difference was found between the subjective complaints and the VaD, AD, or DLB group. Cordonnier et al22 reported the relative prevalence of SHF in a cohort of patients attending a memory clinic. Their odds ratio for microbleeds using patients with subjective complaints as the reference was 15.9 for VaD, 2.1 for AD, and 2.3 for MCI. Because there are some differences between their study and ours, it may be difficult to compare the relative prevalence of SHF between the 2 studies. They used T2*-weighted gradient recalled-echo imaging at 1T, and the mean age of their subgroups was lower than ours. In addition, they did not adjust the odds ratios for age, sex, and hypertension, and they did not perform subgroup analysis of patients with DLB and FTLD.

Carbon 11 Pittsburgh Compound B studies revealed high β-amyloid cortical binding in almost all patients with AD,38,39 in 60% of those with MCI,39 and in >50% those with DLB40,41; in 25% of patients with FTLD, binding was low.42 Among the neurodegenerative dementia groups, the order of the prevalence of β-amyloid binding was similar to that of the relative prevalence of SHF in our study. On the basis of neuropathologic studies,23,43 microbleeds are frequently observed in the brains of patients with AD and are mainly related to β-amyloid pathology (cerebral amyloid angiopathy). Moreover, a neuropathologic study showed a relatively high prevalence of β-amyloid pathology and cortical microhemorrhages in the brains of patients with DLB27,44 and a low prevalence of β-amyloid pathology in patients with FTLD.27,45 We suggest that SHF on SWI may be associated with β-amyloid pathology in these diseases.

In all of our patient groups, the lobar region was the most frequent site of SHF. Although in patients with AD, DLB, and FTLD, there was a significant predilection for the lobar region, this was not the case in patients with VaD, MCI, and subjective complaints. SHF in the basal ganglia/thalamus or infratentorial region tend to be associated with vascular risk factors.11 In patients with MCI, the distribution pattern of SHF was more similar to VaD than AD. Staekenborg et al46 demonstrated that microbleeds, lacunar infarctions, and severe white matter hyperintensities in MCI were associated with progression to non-AD dementia such as VaD. In our patients with MCI, lacunar infarctions and confluent white matter hypertensities were seen in 26% and 16% of patients, respectively. Although we did not evaluate the progression of MCI to dementia in this study, the patients with small-vessel disease may have affected the distribution pattern of the microbleeds in MCI.

We observed that in patients with VaD, their SHF were almost equally distributed among the lobar, basal ganglia/thalamus, and infratentorial regions. This SHF distribution may be explained as follows: Because cerebral amyloid angiopathy has a lobar predilection and is associated with advancing age,47 it may have coexisted with lipohyalinosis in our elderly patients with VaD. Then, lobar SHF do not include periventricular or deep white matter according to the Microbleed Anatomical Rating Scale.48 Because we defined periventricular or deep white matter SHF as a lobar region, the definition may have affected the anatomic prevalence. In addition, our observers scaled a region as SHF-positive if they identified at least 1 small hypointense focus in an area or region. This assessment method may have influenced our results.

The distribution pattern of the microbleeds in patients with FTLD was similar to that in AD. A study of postmortem MR imaging by De Reuck et al49 demonstrated that microbleeds in patients with FTLD had a lobar prevalence. Their pathologic study revealed that cerebral amyloid angiopathy does not explain all of the microbleeds in the brain. Although the exact causes of microbleeds in patients with FTLD are not known, they suggested that microbleeds were associated with disturbances of the blood-brain barrier due to the severity of neurodegeneration.

Our study confirms earlier reports that documented the lobar distribution of SHF in AD.19,22,23,25 According to Pettersen et al,19 in patients with AD, SHF are primarily found at occipital sites. Among our patients with AD, there was no significant difference in the location of SHF in frontal, temporal, parietal, and occipital areas. When our observers identified at least 1 small hypointense focus, the area was recorded as SHF-positive. Our evaluation method differed from theirs, and this discrepancy may account for the difference. We did not evaluate the degree of accumulation of SHF in a specific area of the brain.

In our study, SHF were topographically similar in patients with AD and DLB because they manifested a predilection for the lobar region. We cannot explain the apparent preference for this region in patients with DLB. Earlier neuropathologic studies showed a relatively high prevalence of AD pathology and lobar microhemorrhages, including cerebral amyloid angiopathy pathology, in individuals with DLB.27,44 These findings support ours. Because our DLB group was of the most advanced mean age, the age factor might have played a role in the induction of cerebral amyloid angiopathy pathology in this group.

Our study has some limitations. First, patients with subjective complaints served as the control. In our subjective complaints group, lacunar infarcts were not observed and the frequency of confluent white matter hyperintensities was very low. Therefore, we think that the effect of small-vessel disease in our patients with subjective complaints was small. The prevalence of lobar SHF among elderly healthy controls with a mean age of 74.6 years reported by Yates et al,21 who used 3T SWI, was similar to ours. The mean age of our patients with subjective complaints was slightly lower than theirs. Subjective memory symptoms might be related to preclinical AD and, therefore, may be artificially increasing the number of microbleeds expected in the control group. Second, the number of patients in our subgroups was relatively small, and 3T SWI studies on larger populations are needed to elucidate the prevalence and topography of SHF in patients with dementia. Third, our study had a lack of pathologic confirmation of microbleeds. Schrag et al50 reported a correlative study of 3T SWI-identified hypointense foci to tissue pathology in postmortem brains of patients with AD. The correlation showed a variety of cerebral amyloid angiopathy–related pathologies: acute microhemorrhage, hemosiderin residua of old hemorrhages, and small lacunes ringed by hemosiderin. Their study suggests that hypointense foci on SWI in patients with AD indicate a variety of cerebral amyloid angiopathy–related pathologies. Finally, all diagnoses were based on pre-established clinical criteria without biomarker support of amyloid pathology or pathologic confirmation. This may create some errors in the associations.

Conclusions

The prevalence of SHF suggesting microbleeds on 3T SWI among the groups differed significantly; 86% of those with VaD, 54% of those with DLB, 48% of those with AD, 41% of those with MCI, 27% of those with FTLD, and 22% of those with subjective complaints harbored SHF. The adjusted odds ratio for SHF by using the subjective complaints group as a reference was 9.2 for VaD, 5.4 for AD, 3.1 for DLB, 2.0 for MCI, and 1.5 for FTLD. Patients with AD, DLB, and FTLD manifested a lobar predilection. Our findings provide further evidence not only for the involvement of vascular factors in these neurodegenerative diseases but also that SHF may even relate to amyloid pathology in specific diseases. Further studies are necessary to investigate the relationship of microbleeds to the disease pathogenesis, disease progression, and prognosis.

References

  1. 1.↵
    1. Ferri CP,
    2. Prince M,
    3. Brayne C,
    4. et al
    . Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112–17
    CrossRefPubMed
  2. 2.↵
    1. Matthews FE,
    2. Brayne C,
    3. Lowe J,
    4. et al
    . Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 2009;6:e1000180
    CrossRefPubMed
  3. 3.↵
    1. Langbaum JB,
    2. Chen K,
    3. Lee W,
    4. et al
    . Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009;45:1107–16
    CrossRefPubMed
  4. 4.↵
    1. Ikeda M,
    2. Hokoishi K,
    3. Maki N,
    4. et al
    . Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. Neurology 2001;57:839–44
    CrossRef
  5. 5.↵
    1. Garre-Olmo J,
    2. Genis Batlle D,
    3. del Mar Fernandez M,
    4. et al
    . Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology 2010;75:1249–55
    CrossRef
  6. 6.↵
    1. Jellinger KA,
    2. Attems J
    . Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders. Dement Geriatr Cogn Disord 2011;31:309–16
    CrossRefPubMed
  7. 7.↵
    1. Greenberg SM,
    2. Finklestein SP,
    3. Schaefer PW
    . Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996;46:1751–54
    CrossRef
  8. 8.↵
    1. Fazekas F,
    2. Kleinert R,
    3. Roob G,
    4. et al
    . Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999;20:637–42
    Abstract/FREE Full Text
  9. 9.↵
    1. Nandigam RN,
    2. Viswanathan A,
    3. Delgado P,
    4. et al
    . MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol 2009;30:338–43
    Abstract/FREE Full Text
  10. 10.↵
    1. Cordonnier C,
    2. Al-Shahi Salman R,
    3. Wardlaw J
    . Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 2007;130:1988–2003
    Abstract/FREE Full Text
  11. 11.↵
    1. Vernooij MW,
    2. van der Lugt A,
    3. Ikram MA,
    4. et al
    . Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008;70:1208–14
    CrossRef
  12. 12.↵
    1. Henskens LH,
    2. van Oostenbrugge RJ,
    3. Kroon AA,
    4. et al
    . Brain microbleeds are associated with ambulatory blood pressure levels in a hypertensive population. Hypertension 2008;51:62–68
    CrossRef
  13. 13.↵
    1. Sveinbjornsdottir S,
    2. Sigurdsson S,
    3. Aspelund T,
    4. et al
    . Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry 2008;79:1002–06
    Abstract/FREE Full Text
  14. 14.↵
    1. Jeerakathil T,
    2. Wolf PA,
    3. Beiser A,
    4. et al
    . Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 2004;35:1831–35
    Abstract/FREE Full Text
  15. 15.↵
    1. Poels MM,
    2. Vernooij MW,
    3. Ikram MA,
    4. et al
    . Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam Scan Study. Stroke 2010;41:S103–06
    Abstract/FREE Full Text
  16. 16.↵
    1. Jeong SW,
    2. Jung KH,
    3. Chu K,
    4. et al
    . Clinical and radiologic differences between primary intracerebral hemorrhage with and without microbleeds on gradient-echo magnetic resonance images. Arch Neurol 2004;61:905–09
    CrossRefPubMed
  17. 17.↵
    1. Kato H,
    2. Izumiyama M,
    3. Izumiyama K,
    4. et al
    . Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 2002;33:1536–40
    Abstract/FREE Full Text
  18. 18.↵
    1. Wardlaw JM,
    2. Lewis SC,
    3. Keir SL,
    4. et al
    . Cerebral microbleeds are associated with lacunar stroke defined clinically and radiologically, independently of white matter lesions. Stroke 2006;37:2633–36
    Abstract/FREE Full Text
  19. 19.↵
    1. Pettersen JA,
    2. Sathiyamoorthy G,
    3. Gao FQ,
    4. et al
    . Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia Study. Arch Neurol 2008;65:790–95
    CrossRefPubMed
  20. 20.↵
    1. Greenberg SM,
    2. Vernooij MW,
    3. Cordonnier C,
    4. et al
    . Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165–74
    CrossRefPubMed
  21. 21.↵
    1. Yates PA,
    2. Sirisriro R,
    3. Villemagne VL,
    4. et al
    . Cerebral microhemorrhage and brain beta-amyloid in aging and Alzheimer disease. Neurology 2011;77:48–54
    CrossRef
  22. 22.↵
    1. Cordonnier C,
    2. van der Flier WM,
    3. Sluimer JD,
    4. et al
    . Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006;66:1356–60
    CrossRef
  23. 23.↵
    1. Nakata-Kudo Y,
    2. Mizuno T,
    3. Yamada K,
    4. et al
    . Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 2006;22:8–14
    PubMed
  24. 24.↵
    1. Vernooij MW,
    2. Ikram MA,
    3. Wielopolski PA,
    4. et al
    . Cerebral microbleeds: accelerated 3D T2*-weighted GRE MR imaging versus conventional 2D T2*-weighted GRE MR imaging for detection. Radiology 2008;248:272–77
    CrossRefPubMed
  25. 25.↵
    1. Hanyu H,
    2. Tanaka Y,
    3. Shimizu S,
    4. et al
    . Cerebral microbleeds in Alzheimer's disease. J Neurol 2003;250:1496–97
    CrossRefPubMed
  26. 26.↵
    1. Seo S,
    2. Hwa Lee B,
    3. Kim EJ,
    4. et al
    . Clinical significance of microbleeds in subcortical vascular dementia. Stroke 2007;38:1949–51
    Abstract/FREE Full Text
  27. 27.↵
    1. De Reuck J,
    2. Deramecourt V,
    3. Cordonnier C,
    4. et al
    . Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: a neuropathological study. J Neurol Sci 2011;300:63–66
    CrossRefPubMed
  28. 28.↵
    1. Goos JD,
    2. van der Flier WM,
    3. Knol DL,
    4. et al
    . Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. Stroke 2011;42:1894–900
    Abstract/FREE Full Text
  29. 29.↵
    1. McKhann G,
    2. Drachman D,
    3. Folstein M,
    4. et al
    . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44
    CrossRefPubMed
  30. 30.↵
    1. Román GC,
    2. Tatemichi TK,
    3. Erkinjuntti T,
    4. et al
    . Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–60
    CrossRef
  31. 31.↵
    1. Winblad B,
    2. Palmer K,
    3. Kivipelto M,
    4. et al
    . Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–46
    CrossRefPubMed
  32. 32.↵
    1. McKeith IG,
    2. Dickson DW,
    3. Lowe J,
    4. et al
    . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72
    CrossRef
  33. 33.↵
    1. Neary D,
    2. Snowden JS,
    3. Gustafson L,
    4. et al
    . Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–54
    CrossRef
  34. 34.↵
    1. Sehgal V,
    2. Delproposto Z,
    3. Haacke EM,
    4. et al
    . Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005;22:439–50
    CrossRefPubMed
  35. 35.↵
    1. Fazekas F,
    2. Chawluk JB,
    3. Alavi A,
    4. et al
    . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351–56
    CrossRefPubMed
  36. 36.↵
    1. Tong KA,
    2. Ashwal S,
    3. Holshouser BA,
    4. et al
    . Hemorrhagic shearing lesions in children and adolescents with posttraumatic diffuse axonal injury: improved detection and initial results. Radiology 2003;227:332–39
    CrossRefPubMed
  37. 37.↵
    1. Theysohn JM,
    2. Kraff O,
    3. Maderwald S,
    4. et al
    . 7 Tesla MRI of microbleeds and white matter lesions as seen in vascular dementia. J Magn Reson Imaging 2011;33:782–91
    CrossRefPubMed
  38. 38.↵
    1. Klunk WE,
    2. Engler H,
    3. Nordberg A,
    4. et al
    . Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19
    CrossRefPubMed
  39. 39.↵
    1. Rowe CC,
    2. Ng S,
    3. Ackermann U,
    4. et al
    . Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718–25
    CrossRef
  40. 40.↵
    1. Edison P,
    2. Rowe CC,
    3. Rinne JO,
    4. et al
    . Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331–38
    Abstract/FREE Full Text
  41. 41.↵
    1. Gomperts SN,
    2. Rentz DM,
    3. Moran E,
    4. et al
    . Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903–10
    CrossRef
  42. 42.↵
    1. Rabinovici GD,
    2. Furst AJ,
    3. O'Neil JP,
    4. et al
    . 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007;68:1205–12
    CrossRef
  43. 43.↵
    1. Ellis RJ,
    2. Olichney JM,
    3. Thal LJ,
    4. et al
    . Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996;46:1592–96
    CrossRef
  44. 44.↵
    1. Jellinger KA,
    2. Attems J
    . Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm 2008;115:473–82
    CrossRefPubMed
  45. 45.↵
    1. Knopman DS,
    2. Boeve BF,
    3. Parisi JE,
    4. et al
    . Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol 2005;57:480–88
    CrossRefPubMed
  46. 46.↵
    1. Staekenborg SS,
    2. Koedam EL,
    3. Henneman WJ,
    4. et al
    . Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 2009;40:1269–74
    Abstract/FREE Full Text
  47. 47.↵
    1. Biffi A,
    2. Greenberg SM
    . Cerebral amyloid angiopathy: a systematic review. J Clin Neurol 2011;7:1–9
    CrossRefPubMed
  48. 48.↵
    1. Gregoire SM,
    2. Chaudhary UJ,
    3. Brown MM,
    4. et al
    . The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology 2009;73:1759–66
    CrossRef
  49. 49.↵
    1. De Reuck J,
    2. Deramecourt V,
    3. Cordonnier C,
    4. et al
    . Detection of microbleeds in post-mortem brains of patients with frontotemporal lobar degeneration: a 7.0-Tesla magnetic resonance imaging study with neuropathological correlates. Eur J Neurol 2012;19:1355–60
    CrossRefPubMed
  50. 50.↵
    1. Schrag M,
    2. McAuley G,
    3. Pomakian J,
    4. et al
    . Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol 2010;119:291–302
    CrossRefPubMed
  • Received May 23, 2012.
  • Accepted after revision July 31, 2012.
  • © 2013 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 34 (5)
American Journal of Neuroradiology
Vol. 34, Issue 5
1 May 2013
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence and Topography of Small Hypointense Foci Suggesting Microbleeds on 3T Susceptibility-Weighted Imaging in Various Types of Dementia
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
H. Uetani, T. Hirai, M. Hashimoto, M. Ikeda, M. Kitajima, F. Sakamoto, D. Utsunomiya, S. Oda, S. Sugiyama, J. Matsubara, Y. Yamashita
Prevalence and Topography of Small Hypointense Foci Suggesting Microbleeds on 3T Susceptibility-Weighted Imaging in Various Types of Dementia
American Journal of Neuroradiology May 2013, 34 (5) 984-989; DOI: 10.3174/ajnr.A3332

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Prevalence and Topography of Small Hypointense Foci Suggesting Microbleeds on 3T Susceptibility-Weighted Imaging in Various Types of Dementia
H. Uetani, T. Hirai, M. Hashimoto, M. Ikeda, M. Kitajima, F. Sakamoto, D. Utsunomiya, S. Oda, S. Sugiyama, J. Matsubara, Y. Yamashita
American Journal of Neuroradiology May 2013, 34 (5) 984-989; DOI: 10.3174/ajnr.A3332
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • References
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Maximum AmbiGuity Distance for Phase Imaging in Detection of Traumatic Cerebral Microbleeds: An Improvement over Current Imaging Practice
  • Clinicoradiologic Correlations of Cerebral Microbleeds in Advanced Age
  • Diagnostic Significance of Cortical Superficial Siderosis for Alzheimer Disease in Patients with Cognitive Impairment
  • Prevalence of Brain Microbleeds in Alzheimer Disease: A Systematic Review and Meta-Analysis on the Influence of Neuroimaging Techniques
  • SWI or T2*: Which MRI Sequence to Use in the Detection of Cerebral Microbleeds? The Karolinska Imaging Dementia Study
  • Cerebral Microbleeds: Different Prevalence, Topography, and Risk Factors Depending on Dementia Diagnosis--The Karolinska Imaging Dementia Study
  • Crossref (43)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
    Melanie D. Sweeney, Abhay P. Sagare, Berislav V. Zlokovic
    Nature Reviews Neurology 2018 14 3
  • Blood-Brain Barrier: From Physiology to Disease and Back
    Melanie D. Sweeney, Zhen Zhao, Axel Montagne, Amy R. Nelson, Berislav V. Zlokovic
    Physiological Reviews 2019 99 1
  • The role of brain vasculature in neurodegenerative disorders
    Melanie D. Sweeney, Kassandra Kisler, Axel Montagne, Arthur W. Toga, Berislav V. Zlokovic
    Nature Neuroscience 2018 21 10
  • Cerebral Microbleeds: Imaging and Clinical Significance
    Sven Haller, Meike W. Vernooij, Joost P. A. Kuijer, Elna-Marie Larsson, Hans Rolf Jäger, Frederik Barkhof
    Radiology 2018 287 1
  • Susceptibility‐weighted imaging: current status and future directions
    Saifeng Liu, Sagar Buch, Yongsheng Chen, Hyun‐Seok Choi, Yongming Dai, Charbel Habib, Jiani Hu, Joon‐Yong Jung, Yu Luo, David Utriainen, Meiyun Wang, Dongmei Wu, Shuang Xia, E. Mark Haacke
    NMR in Biomedicine 2017 30 4
  • SWI or T2*: Which MRI Sequence to Use in the Detection of Cerebral Microbleeds? The Karolinska Imaging Dementia Study
    S. Shams, J. Martola, L. Cavallin, T. Granberg, M. Shams, P. Aspelin, L.O. Wahlund, M. Kristoffersen-Wiberg
    American Journal of Neuroradiology 2015 36 6
  • Cerebral Microbleeds: Different Prevalence, Topography, and Risk Factors Depending on Dementia Diagnosis—The Karolinska Imaging Dementia Study
    S. Shams, J. Martola, T. Granberg, X. Li, M. Shams, S.M. Fereshtehnejad, L. Cavallin, P. Aspelin, M. Kristoffersen-Wiberg, L.O. Wahlund
    American Journal of Neuroradiology 2015 36 4
  • Neural stem cell therapy for neurovascular injury in Alzheimer&#039;s disease
    Austin C. Boese, Milton H. Hamblin, Jean-Pyo Lee
    Experimental Neurology 2020 324
  • Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
    Geetika Nehra, Bjoern Bauer, Anika M.S. Hartz
    Pharmacology & Therapeutics 2022 234
  • Interactions between glial cells and the blood-brain barrier and their role in Alzheimer&#039;s disease
    Ming Zhao, Xue-Fan Jiang, Hui-Qin Zhang, Jia-Hui Sun, Hui Pei, Li-Na Ma, Yu Cao, Hao Li
    Ageing Research Reviews 2021 72

More in this TOC Section

  • Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease
  • Evaluating the Effects of White Matter Multiple Sclerosis Lesions on the Volume Estimation of 6 Brain Tissue Segmentation Methods
  • White Matter Alterations in the Brains of Patients with Active, Remitted, and Cured Cushing Syndrome: A DTI Study
Show more Brain

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editors Choice
  • Fellow Journal Club
  • Letters to the Editor

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

Special Collections

  • Special Collections

Resources

  • News and Updates
  • Turn around Times
  • Submit a Manuscript
  • Author Policies
  • Manuscript Submission Guidelines
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Submit a Case
  • Become a Reviewer/Academy of Reviewers
  • Get Peer Review Credit from Publons

Multimedia

  • AJNR Podcast
  • AJNR SCANtastic
  • Video Articles

About Us

  • About AJNR
  • Editorial Board
  • Not an AJNR Subscriber? Join Now
  • Alerts
  • Feedback
  • Advertise with us
  • Librarian Resources
  • Permissions
  • Terms and Conditions

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire